G.3Chapter 8: Phototherapy

G.3.1Phototherapy

In people with psoriasis (all types), what are the clinical effectiveness, safety, tolerability and cost effectiveness of BBUVB, NBUVB and PUVA compared with each other or placebo/no treatment?

Excluded n = 1

Study excludedReason
Hankin CS, Bhatia ND, Goldenberg G et al. A comparison of the clinical effectiveness and cost-effectiveness of treatments for moderate to severe psoriasis. Drug Benefit Trends. 2010; 22(1):17–27. Ref ID: HANKIN2010Partially applicable, very serious limitations

G.3.2Phototherapy combined with acitretin

In people with psoriasis (all types), what are the clinical effectiveness, safety, tolerability and cost effectiveness of acitretin plus UVB (NBUVB and BBUVB) and acitretin plus PUVA compared with their monotherapies and compared with each other?

Excluded n = 1

Excluded StudyReason
Hankin CS, Bhatia ND, Goldenberg G et al. A comparison of the clinical effectiveness and cost-effectiveness of treatments for moderate to severe psoriasis. Drug Benefit Trends. 2010; 22(1):17–27. Ref ID: HANKIN2010Partially applicable, very serious limitations

G.3.3Dithranol, coal tar and vitamin D or vitamin D analogues combined with UVB

In people with psoriasis (all types), what are the clinical effectiveness, safety, tolerability and cost effectiveness of UVB (NBUVB or BBUVB) combined with dithranol, coal tar or vitamin D or vitamin D analogues compared with UVB alone or topical therapy alone?

Excluded n = 2

Study excludedReason
de Rie MA, de Hoop D, Jonsson L et al. Pharmacoeconomic evaluation of calcipotriol (Daivonex/Dovonex) and UVB phototherapy in the treatment of psoriasis: a Markov model for the Netherlands. Dermatology. 2001; 202(1):38–43. Ref ID: DERIE2001Partially applicable, very serious limitations
Hartman M, Prins M, Swinkels OQ et al. Cost-effectiveness analysis of psoriasis care instruction programme with dithranol compared with uvb phototherapy and inpatient dithranol treatment. Br J Dermatol. 2002; 147(3):538–544. Ref ID: HARTMAN2002Not applicable

From: Appendix G, Excluded studies list (cost effectiveness)

Cover of Psoriasis
Psoriasis: Assessment and Management of Psoriasis.
NICE Clinical Guidelines, No. 153.
National Clinical Guideline Centre (UK).
Copyright © National Clinical Guideline Centre - October 2012.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.